Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Community-acquired pneumonia,Acute bacterial sinusitis,Acute bacterial exacerbation of chronic bronchitis,Uncomplicated skin and skin structure infections,Complicated skin and skin structure infections,Complicated intra-abdominal infections,Urinary tract infections,Acute pyelonephritis,Chronic bacterial prostatitis,Inhalational anthrax (post-exposure),Plague
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
400 mg intravenously once daily. Infuse over 60 minutes.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Terminal elimination half-life of moxifloxacin is approximately 11-15 hours in patients with normal renal function; allows once-daily dosing.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Hepatic via glucuronide and sulfate conjugation; CYP450 system not significantly involved.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal (approximately 45-60% as unchanged drug and metabolites); biliary/fecal (approximately 20-25% as unchanged drug and metabolites); total urinary and fecal recovery >95%.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Approximately 40-50% bound to serum proteins, primarily albumin.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Volume of distribution is approximately 2.8 L/kg; indicates extensive tissue penetration, including into lungs, sinuses, skin, and soft tissues.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100% (complete immediate bioavailability).
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
For GFR <30 m L/min, reduce dose to 400 mg intravenously every 48 hours.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No dosage adjustment required for hepatic impairment.
Safety and efficacy not established in pediatric patients under 18 years.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
No routine dosage adjustment required based on age alone; monitor renal function and adjust as per renal impairment guidelines.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Fluoroquinolones, including moxifloxacin, have been associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients older than 60 years, those taking corticosteroids, and those with kidney, heart, or lung transplants. Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis. Avoid use in patients with known history of myasthenia gravis.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
May prolong QT interval; avoid in patients with known QTc prolongation, uncorrected hypokalemia, or receiving class IA or III antiarrhythmics. Use with caution in patients with CNS disorders (e.g., epilepsy). Discontinue if signs of tendon pain, inflammation, or rupture occur. May cause peripheral neuropathy. Use with caution in patients with renal impairment. Avoid in patients with known hypersensitivity to fluoroquinolones.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypersensitivity to moxifloxacin or any fluoroquinolone; history of tendinopathy with fluoroquinolones; patients with myasthenia gravis; pregnancy (category C); nursing mothers; children <18 years; patients with known QTc prolongation or uncorrected electrolyte disturbances.
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No specific food interactions. However, avoid alcohol as it may increase risk of dizziness and gastrointestinal side effects. Keep well hydrated.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Fluoroquinolones, including moxifloxacin, are associated with an increased risk of arthropathy in juvenile animals. In humans, data from pregnant women exposed to fluoroquinolones are limited. First trimester exposure is not associated with major malformations; however, second and third trimester exposure may be linked to fetal bone and cartilage damage. Use during pregnancy should be reserved for infections where no alternatives exist.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Moxifloxacin is excreted into human milk at very low concentrations. The M/P ratio is approximately 0.68. The estimated infant dose is less than 1% of the maternal dose. Caution is advised due to potential for infant joint damage, but no adverse effects reported. Consider interruption of breastfeeding during therapy and for 48 hours after last dose.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy-induced physiological changes (increased volume of distribution, enhanced renal clearance) may lower moxifloxacin plasma concentrations. However, no specific dose adjustments are recommended due to lack of dedicated pharmacokinetic studies in pregnancy. Standard adult dosing (400 mg IV once daily) is used, with caution and consideration of increased clearance potential.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
AVELOX (moxifloxacin) in sodium chloride 0.8% is a fluoroquinolone antibiotic for intravenous use. Avoid rapid infusion; administer over 60 minutes to reduce risk of infusion-related reactions. Monitor for QT prolongation, especially in patients with electrolyte disturbances or on antiarrhythmics. Avoid in patients with known aortic aneurysm or history of tendinopathy. Use caution in elderly and those with renal impairment. Not recommended for patients with myasthenia gravis due to risk of exacerbation.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This medication is given intravenously (IV) and must be infused slowly over at least 60 minutes.,You may experience side effects like nausea, diarrhea, dizziness, or headache. Report severe or persistent symptoms.,Watch for signs of tendon pain or swelling, especially in the shoulder or calf. Stop the medication and seek medical attention if this occurs.,Avoid driving or operating machinery if you experience dizziness or vision changes.,Tell your doctor if you have a history of heart rhythm problems, seizures, or low potassium/magnesium levels.,Use sunscreen and protective clothing to avoid sun sensitivity reactions while on this medication.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is a Electrolyte that works by Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is: 400 mg intravenously once daily. Infuse over 60 minutes.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is classified as Category A/B. Fluoroquinolones, including moxifloxacin, are associated with an increased risk of arthropathy in juvenile animals. In humans, data from pregnant women exposed to fluoroquinolones . AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.